US 11,071,794 B2 · Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application

Abstract

The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.

Claims13

Dependent claims

A compound having Formula II-B:

or a pharmaceutically acceptable salt thereof, wherein:
R2 is CD3;
X is 18F or F;
Y is —[O(CRaRb)2]m—, wherein Ra and Rb are each independently hydrogen or deuterium atoms;
m is 3;
and
A1 is N or CH.

4 more elements

Dependencies are inferred from the claim text.

Facts

Application

16/824,139Filed 19 Mar 2020 · division

Priority

31 May 2017

Published

US 2020/0230263 A123 Jul 2020

Granted

27 Jul 2021

Term ends

Not estimatedThe source records don’t support an estimate.

Classification22 codes

A61K 51/0455
Having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins: having six-membered rings with one nitrogen as the only ring hetero atom
A61B 6/037
Computed tomography [CT]: emission tomography
A61K 51/04
Characterised by the carrier , i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus: organic compounds
A61K 51/0419
Having oxygen as the only ring hetero atom, e.g. fungichromin: having five-membered rings with one oxygen as the only ring hetero atom, e.g.…

Family

Application62/513,217Us provisional application · filed 31 May 2017

Application15/994,474Parent of this division · filed 31 May 2018

US 2020/0230263 A1Pre-grant publication · published 23 Jul 2020

US 10,912,849 B2Parent of this division

US 2018/0344882 A1Published application

US 11,071,794 B2This patent

From the US filing history. Foreign family members aren’t listed.

Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application

Life of this patent

Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application

Life of this patent

Abstract

Claims13